Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsVladimir Coric, MD
Associate Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Appointments
Education & Training
- Fellowship in Forensic Psychiatry
- Yale University School of Medicine (2001)
- Chief Resident, Post-Traumatic Stress Disorder Firm
- National Center for PTSD, VA Connecticut Healthcare System (2000)
- Program-Wide Chief Resident
- Yale University School of Medicine (2000)
- Yale Psychiatry Residency Training Program
- Yale University School of Medicine (2000)
- MD
- Wake Forest University (1996)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Vladimir Coric's published research.
Publications Timeline
A big-picture view of Vladimir Coric's research output by year.
Angeli Landeros-Weisenberger, MD
Michael Bloch, MD, MS
Dan Oren, MD, BS
Christopher van Dyck, MD
Jesse M. Cedarbaum, MD, FAAN (Neurology), FANA
John Krystal, MD
91Publications
3,569Citations
Publications
2026
Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)
Potashman M, Rogula B, Powell L, Korol E, Dickson S, Hendrix S, Heinrich M, Rudell K, Abetz-Webb L, Beiner M, Coric V, Rosenthal L, Perlman S, Schmahmann J, L’Italien G. Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA). Neurology And Therapy 2026, 15: 807-816. PMID: 41706362, PMCID: PMC12965947, DOI: 10.1007/s40120-026-00891-6.Peer-Reviewed Original ResearchAltmetricConceptsCGI-CDisease progressionSpinocerebellar ataxiaClinician Global ImpressionSensitive to disease progressionComposite scoreGlobal ImpressionMeasure disease progressionPatient weightPatientsComposite measureItem weightsPatient preferencesPatient feedbackFace validityFunctional scalesDiscrete symptomsComposite scalePatient perspectiveRegression modelsItem's relative importanceScoresItemsProgressionPatient outcomes in KCNQ2 developmental and epileptic encephalopathy
Maclaine G, Potashman M, Pawar D, Sharma S, Rudell K, Lerner J, Coric V, Berg A, Millichap J, L'Italien G. Patient outcomes in KCNQ2 developmental and epileptic encephalopathy. Developmental Medicine & Child Neurology 2026 PMID: 41527503, DOI: 10.1111/dmcn.70124.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEpileptic encephalopathyKCNQ2-DEEPatient-level dataCaregiver-reportedGross motorSingle-arm trialPatient outcomesWeeks of lifeAged 5Outcome typesMuscle toneObservational studyPatient ageCase reportPatient dataSeizure resolutionKCNQ2Seizure onsetPatientsOnline databasesOutcomesSeizuresSeizure-relatedEarly lifeAge
2025
Development of composite scales for assessing disease progression and treatment effects among patients with Parkinson's disease in a clinical trial setting
L'Italien G, Rogula B, Powell L, Potashman M, Dickson S, Kozauer N, O'Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Dubow J, Rosenthal L, Hendrix S, Database C. Development of composite scales for assessing disease progression and treatment effects among patients with Parkinson's disease in a clinical trial setting. Parkinsonism & Related Disorders 2025, 141: 108077. PMID: 41106090, DOI: 10.1016/j.parkreldis.2025.108077.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsClinical trial dataPlacebo armClinical trialsDisease progressionEarly PDTrial dataParkinson's diseaseClinical trial settingSensitive to disease progressionMDS-UPDRSMDS-UPDRS PartUntreated diseaseParkinson's Disease Rating ScaleDopaminergic therapyParts II and IIIDisease Rating ScaleMovement Disorder Society Unified Parkinson's Disease Rating ScalePDQ-39Placebo arm of clinical trialsTrial settingDisease severityClinical declinePatientsComposite scaleRating ScaleUnderstanding lived experiences with KCNQ2 developmental and epileptic encephalopathy
Potashman M, Rudell K, Abetz-Webb L, Suminski N, Gold A, Doma R, Jarodia K, Buckley C, Ridley M, Lerner J, Mather J, Coric V, Numis A, Sands T, Millichap J, Berg A, L'Italien G. Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy. Epilepsy & Behavior 2025, 172: 110670. PMID: 40912075, DOI: 10.1016/j.yebeh.2025.110670.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsParents of childrenMotor problemsGross motor problemsDevelopment of measurement toolsOutcome domainsChildren's developmental abilitiesPersonal careQualitative interviewsOutcome measuresBothersome issuesMeasurement toolsAge groupsBothersome symptomsKCNQ2-DEEImpact of seizuresChild developmentNeurodevelopmental impairmentPost-infancyChildrenInterviewsEpileptic encephalopathyParentsOutcomesBehavioral disordersCognitive delay1961-LB: Targeted Degradation of Pathogenic Proinsulin and Insulin Autoantibodies with TRAP for the Treatment of Type 1 Diabetes
SPLIID C, RASILE B, ESTRELLA A, YOUSUF H, CARMEN S, BUNIN A, LINHARES B, PICCHIONE K, DENTON R, MARCIN L, PIRMAN D, INGALE S, VIDAL C, CORIC V, CAR B. 1961-LB: Targeted Degradation of Pathogenic Proinsulin and Insulin Autoantibodies with TRAP for the Treatment of Type 1 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-1961-lb.Peer-Reviewed Original ResearchAltmetricConceptsRemoval of aberrant proteinsTargeted degradationInsulin receptorEndosome-lysosome pathwayB cell proteinsIn vivo activityType 1 diabetesAberrant proteinsEndosome-lysosomeAsialoglycoprotein receptorPancreatic islet B cellsOrgan-specific autoimmune diseasesIslet B cellsPotential new treatmentB-cell massPatient serum samplesTreatment of type 1 diabetesTargeted removalSurface plasmon resonanceNOD miceProteinCellular in vitro assaysInsulin productionAutoimmune responseB cellsDevelopment and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson’s Disease
L’Italien G, Rogula B, Powell L, Potashman M, Dickson S, Kozauer N, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Dubow J, Rosenthal L, Hendrix S. Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson’s Disease. Neurology And Therapy 2025, 14: 1609-1625. PMID: 40518466, PMCID: PMC12255624, DOI: 10.1007/s40120-025-00771-5.Peer-Reviewed Original ResearchCitationsConceptsDisease progressionDisease stageCohort of patientsParkinson's Progression Markers InitiativeParkinson's diseasePresence of motor complicationsStage of diseaseMDS-UPDRS Part IMDS-UPDRSEarly-stage PDParkinson's Disease Rating ScaleMotor complicationsDopaminergic treatmentDisease Rating ScaleMovement Disorder Society Unified Parkinson's Disease Rating ScaleUrinary problemsTreatment statusCohortClinical declineMean-to-standard deviation ratioRating ScaleDiseaseProgression Markers InitiativeBHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson’s Disease Mouse Model (S4.006)
Liang C, Tang W, Shankar B, Car B, Qureshi I, Coric V, Lair L. BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson’s Disease Mouse Model (S4.006). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000208701.Peer-Reviewed Original ResearchConceptsRe-weighting MDS-UPDRS Part II and PDQ-39 Items to Detect Maximal Decline in Activities of Daily Living in Untreated Parkinson’s disease (P7-5.015)
L’Italien G, Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Rosenthal L, Hendrix S. Re-weighting MDS-UPDRS Part II and PDQ-39 Items to Detect Maximal Decline in Activities of Daily Living in Untreated Parkinson’s disease (P7-5.015). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000208757.Peer-Reviewed Original ResearchRe-weighting MDS-UPDRS Parts II and III Items to Improve Assessment of Motor Decline in Untreated Parkinson’s Disease (P7-5.014)
Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Rosenthal L, Hendrix S, L’Italien G. Re-weighting MDS-UPDRS Parts II and III Items to Improve Assessment of Motor Decline in Untreated Parkinson’s Disease (P7-5.014). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000208766.Peer-Reviewed Original ResearchComparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods (P6-5.012)
L’Italien G, Potashman M, Beiner M, Rogula B, Powell L, Wirtz V, Stock D, Qureshi I, Kuo S, Rosenthal L, Perlman S, Coric V, Schmahmann J. Comparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods (P6-5.012). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000209018.Peer-Reviewed Original ResearchAltmetric
News
Copy Link
News
Get In Touch
Copy Link